Editorial Policy

Our editorial policy defines how GenoMethods selects, reports, checks and updates biotechnology coverage.

Topic selection

We select stories for scientific importance, public relevance, clinical consequence, market signal and methodological novelty. A discovery is newsworthy when it changes what readers can understand, test, build, regulate or use.

We give priority to primary literature, regulatory documents, trial registries, company disclosures, datasets, technical documentation and direct expert context. Press announcements can start reporting, but they do not end it.

Article types

News reports cover material developments. Analysis explains meaning and consequence. Explainers teach a subject from first principles. Reviews assess tools, products and platforms. Profiles examine companies, laboratories and people. Investigative pieces follow documents, claims and incentives over time.

Opinion is clearly framed as argument. It still requires accurate facts, named assumptions and links to evidence. We do not let persuasive writing replace verification.

Evidence and updates

For technical articles, we identify the method, dataset, cohort, endpoint, model, assay, sample size or benchmark that supports the claim. When a study changes, a trial reads out, a label is updated or a dataset is corrected, we update the article and mark the change inside the text.

Archive materials are treated as primary historical sources. We preserve dates, names and original context while explaining how the field has changed since publication.